leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 10:56:57 - browse：71117

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Q&A: Jennifer Adair on making gene therapy available globally

knowledge

WSS

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Why does health care cost so much? A reading guide

MassMutual is introducing free genetic testing for members

Congressmen charge Covid hearing ‘could have been an email’

The real point of Kenneth Smith’s execution by nitrogen gas

Covid misinformation case heads to Supreme Court

hotspot

leisure time

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Some dementia cases could be undiagnosed liver disease

State Dept. review finds Biden bears some blame for Afghanistan failures

Quicker fix for pulse oximeters urged during FDA public meeting

23andMe had bad news about my health. I wish a person had delivered it

Covid misinformation case heads to Supreme Court

State Dept. review finds Biden bears some blame for Afghanistan failures

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Alkermes shareholders re

SAMSHA loosens regulations on methadone treatment centers

knowledge

Cognito secures funding to test medical device for Alzheimer's

Even great ERs can’t make up for American health disparities

Cognito secures funding to test medical device for Alzheimer's

Melinda French Gates resigns from Gates Foundation

ARCH Venture Partners is raising $3 billion for a life sciences fund

Diversity in clinical trials starts with building trust, experts say

hotspot

knowledge

knowledge

focus